GENERATIVE AI & MACHINE LEARNING TO HELP HEALTH CARE PROVIDERS EXPEDITE CLINICAL AND OPERATIONAL WORKFLOWS : GE HealthCare looks to unlock patient care opportunities in unused data estimated in Deloitte report
People In Health Care
Amit Yadav, CEO GE HealthCare Australia & New Zealand
Filmed Sydney, New South Wales | October 2024
Amit Yadav holds the position of CEO at GE HealthCare in Australia and New Zealand, where he oversees a team of 450 skilled professionals focused on delivering healthcare solutions, particularly in the areas of diagnostic imaging, monitoring, and ultrasound. Talking with Australian Health Journal, Amit has background as a clinical radiographer, evolving into roles at GE, where he gained expertise as a CT trainer and later commercial responsibilities.
Drawing from GE’s 125-year legacy in healthcare, Amit is leading efforts to integrate AI into medical imaging devices and optimise workflow efficiencies. He stresses the importance of leveraging the vast amount of untapped healthcare data, with an emphasis on automating manual processes to enhance productivity. Additionally, his focus extends to utilising AI for workflow optimisation and ensuring compliance with local regulations and standards to prioritise safety.
Amit places significant emphasis on educating healthcare professionals about the capabilities and limitations of AI and digital solutions. Collaborating with partners such as Amazon Web Services (AWS), he aims to implement user-friendly enterprise-wide solutions that cater to the needs of clinicians. Amit also recognises the necessity of continuous education and training programs for healthcare professionals, working closely with colleges and universities to integrate AI and digital education at various levels.
Furthermore, Amit is actively involved in fostering partnerships with educational institutions to develop training and education programs for the next generation of healthcare leaders. He emphasises the need for a comprehensive understanding of AI’s implications in patient treatment and advocates for personalised approaches to healthcare outcomes. Amit’s commitment to advancing healthcare through innovation and education underscores GE HealthCare’s dedication to driving positive change in the industry.
-
In development, age specific clinical practice guidelines for early onset bowel cancer
The National Health and Medical Research Council (NHMRC) has agreed to consider for approval the Clinical Practice Guidelines for the Early Diagnosis and Management of Early-Onset Colorectal Cancer (EOCRC), to be developed by Bowel Cancer Australia in collaboration with the Australian Living Evidence Collaboration (ALEC), and funded by Bowel Cancer Australia. ALEC is led by Cochrane Australia and based in the School of Public Health and Preventive Medicine at Monash University.
-
NSW Medical Device Commercialisation Training Program (MDCTP) Graduation 2019
Cicada Innovations with NSW Health this week hosted the graduation night for the 15 individuals that were part of the NSW Medical Device Commercialisation Training Program (MDCTP).
-
The role of genomic screening in transforming public health
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
